Income statement, balance sheet and cash flow statement for the last 2 fiscal years, taken from the XBRL data NERVGEN PHARMA CORP. files with the SEC in its annual reports.
In CAD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
FY2025
Research and development
15.8
13.9
Interest income
0.81
0.33
Net income
-24.3
-44.1
EPS, basic
-0.36
-0.61
EPS, diluted
-0.36
-0.61
Balance sheet
FY2025
FY2025
Cash and equivalents
17.3
22.1
Receivables
0.42
0.08
Total current assets
19
22.8
Intangible assets
0.46
0.41
Total assets
19.5
23.2
Accounts payable
4.94
4.66
Total current liabilities
16.9
19.7
Lease liabilities
0.01
Total liabilities
16.9
19.7
Retained earnings
-103
-147
Total equity
2.58
3.48
Total liabilities and equity
19.5
23.2
Cash flow statement
FY2025
FY2025
Net income
-24.3
-44.1
Cash from operations
-16.8
-19.5
Cash from investing
0.06
0.1
Stock issued
23
16.9
Cash from financing
22.7
23.8
Exchange rate effect
-0.31
0.44
Net change in cash
5.61
4.8
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-206.7%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
19.1%
Total assets vs the same period a year earlier. Only from a positive base.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.16x
Current assets / current liabilities.
Quick ratio
1.12x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.12x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
85.0%
Total liabilities / total assets.
Working capital
CA$3.1M
Current assets - current liabilities.
Goodwill and intangibles / assets
1.8%
(Goodwill + intangible assets) / total assets.
Per share
Metric
Value
How it is calculated
EPS, diluted
-CA$0.61
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-CA$0.61
Net income per basic share, as reported (split-adjusted).
Was NERVGEN PHARMA CORP. profitable in fiscal 2025?
No. It reported a net loss of CA$44.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.